en
Scientific article
Open access
English

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients

Published inOpen forum infectious diseases, vol. 10, no. 4, ofad169
Publication date2023-04-01
First online date2023-03-27
Abstract

In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuation, predominately in haploidentical HCT recipients, without any associations with CMV-DNAemia under letermovir.

eng
Keywords
  • Allogeneic hematopoietic cell transplant recipients (allo-HCTr)
  • Breakthrough infection
  • Cytomegalovirus (CMV)
  • Letermovir
  • Prophylaxis
  • Risk factors
Citation (ISO format)
CHAVAZ, Lara Marie et al. CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients. In: Open forum infectious diseases, 2023, vol. 10, n° 4, p. ofad169. doi: 10.1093/ofid/ofad169
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
ISSN of the journal2328-8957
28views
3downloads

Technical informations

Creation10/10/2023 9:20:33 AM
First validation02/14/2024 9:47:25 AM
Update time02/14/2024 9:47:25 AM
Status update02/14/2024 9:47:25 AM
Last indexation05/06/2024 5:56:13 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack